Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
IR Contact
News
-
January 22, 2020Reminder: Targovax ASA – Invitation to investor call
-
January 21, 2020Targovax ASA: Invitation to investor call
-
January 21, 2020Targovax announces encouraging data in mesothelioma study combining ONCOS-102 and standard of care chemotherapy
-
January 8, 2020Targovax and IOVaxis Therapeutics enters Option Agreement for TG mutant RAS vaccine license and clinical development in China
Third quarter 2019
Was published on November 7, 2019